ClinicalTrials.gg
CompletedNCT03052751Updated Aug 3, 2021Results posted

Study to Test the Safety, Tolerability and Efficacy of UCB7665 in Subjects With Moderate to Severe Myasthenia Gravis

A Phase 2 interventional study of UCB7665 and Placebo in Myasthenia Gravis, sponsored by UCB Biopharma S.P.R.L.. Completed at 20 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-08-03.

Sponsored by UCB Biopharma S.P.R.L. (part of UCB S.A.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
43
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing rozanolixizumab in Myasthenia Gravis — 2 open to participants now, 4 under way, 3 of them phase 3. rozanolixizumab · Myasthenia Gravis.

Enrollment
7th of 10
43 · median 67
Started
2017
the only one that year
Phase 2
Only one
of the 10
Registered
1st of 10
by date
Lead sponsor
1 of 10
UCB Biopharma S.P.R.L.

Among the 10 studies testing rozanolixizumab in Myasthenia Gravis, this one is the 7th largest by enrollment, is the only one that started in 2017, is the only one in phase 2, and was the 1st registered.

Myasthenia Gravis

331 studies on the registry are indexed under Myasthenia Gravis; 145 are open to participants now.

Browse Myasthenia Gravis studies →

Open to participants now

2 of the 10 studies testing rozanolixizumab in Myasthenia Gravis are open now, in 9 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About rozanolixizumab

rozanolixizumab: first FDA approval 2023 (RYSTIGGO), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 104 Myasthenia Gravis studies recruiting now, 64 (62%) set no upper age limit and 23 (22%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing rozanolixizumab in Myasthenia Gravis, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate the clinical efficacy of UCB7665 as a chronic-intermittent treatment in subjects with generalized myasthenia gravis (MG) who are classified as moderate to severe.

03

Conditions studied

  • Myasthenia Gravis

Browse trials for

Keywords

  • UCB7665
  • Myasthenia Gravis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject has a well-documented diagnosis of myasthenia gravis (MG) at Visit 1 (Screening), based on subject history and supported by previous evaluations
  • Subject would currently be considered for treatment with immunological therapy (immunoglobulin/plasma exchange (IVIG/PLEX)) by the investigator
  • Subject has a well-documented record of autoantibodies against anti-acetylcholine receptor (Anti-AChR) or anti-muscle specific kinase (Anti-MuSK) prior to Screening
  • Female subjects must either be: , permanently sterilized or if applicable will use a highly effective method of
  • Male subjects must be willing to use a method of contraception

Exclusion criteria

Exclusion Criteria:

  • Subject has previously received treatment in this study or subject has previously been exposed to UCB7665
  • Subject has participated in another study of an medicinal product (IMP; or a medical device) within the previous 30 days of Screening or is currently participating in another study of an investigational medicinal product (IMP; or a medical device)
  • Subject has a known to any components of the IMP
  • Subject has a history of hyperprolinemia, since L-proline is a constituent of the UCB7665 IMP
  • Subjects with Myasthenia Gravis (MG) only affecting the ocular muscles
  • Subjects with severe weakness affecting oropharyngeal or respiratory muscles, or who have myasthenic crisis at Screening or impending crisis
  • Subject has quantitative myasthenia gravis (QMG) score of \<11 at Baseline
  • Subject has a serum total immunoglobulin G (IgG) level \<= 6g/L at Screening
  • \<1500 cells/mm\^3
  • Subject has any medical condition (acute or chronic illness) or psychiatric condition that, in the opinion of the investigator, could jeopardize or would compromise the subject's ability to participate in this study
  • Subject has any laboratory abnormality that, in the opinion of the investigator, is , has not resolved at randomization, and could jeopardize or would compromise the subject's ability to participate in this study
  • Subject has received a within 8 weeks prior to the Baseline Visit; or intends to have a live vaccination during the course of the study or within 7 weeks following the final dose of IMP
  • Subject has received any experimental biological agent within or outside of a clinical study in the past 3 months or within 5 half-lives prior to Baseline (whichever is longer)
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
43 participants (actual)

Study arms

  • Experimental
    Dosage Regimen 1

    Subjects randomized in dosage regimen 1 will receive 3 doses of UCB7655 (dose 1) in dosing period 1 and will then be re-randomized into dosing period 2 to receive 3 doses of UCB7665 (dose 1 or dose 2).

    Drug: UCB7665

  • Experimental
    Dosage Regimen 2

    Subjects randomized in dosage regimen 2 will receive 3 doses of placebo in dosing period 1 and will then be re-randomized into dosing period 2 to receive 3 doses of UCB7665 (dose 1 or dose 2).

    Drug: UCB7665 · Other: Placebo

Interventions

  • UCB7665 will be administered in 2 different dosages (dose 1 and dose 2). UCB7665 (INN: Rozanolixizumab) is a humanized monoclonal antibody that is being developed for treatment of IgG autoantibody-mediated conditions such as myasthenia gravis (MG)

    Also known as: Rozanolixizumab

  • OtherPlacebo

    Placebo will be administered in period 1 of dosage regimen 2.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Quantitative Myasthenia Gravis (QMG) Score to Visit 9

    The total QMG score was obtained by summing the responses to each individual item (13 items; Responses: None=0, Mild=1, Moderate=2, Severe=3). The score ranges from 0 to 39, with lower scores indicating lower disease activity. The change from Baseline is calculated, a negative value indicating improvement and a positive value worsening.

    Time frame: From Baseline to Visit 9 (up to Day 29)

Secondary outcomes

  1. Change From Baseline in Myasthenia Gravis-Composite Score to Visit 9

    The total Myasthenia Gravis (MG)-composite score was obtained by summing the responses to each individual item (10 items; Grade: 0-9 depending on item). The score ranges from 0 to 50, with lower scores indicating lower disease activity. The change from Baseline is calculated, a negative value indicating improvement and a positive value worsening.

    Time frame: From Baseline to Visit 9 (up to Day 29)

  2. Change From Baseline in Myasthenia Gravis-Activities of Daily Living (MGADL) Score to Visit 9

    The total MGDAL score was obtained by summing the responses to each individual item (8 items; Grades: 0, 1, 2, 3). The score ranges from 0 to 24, with lower scores indicating lower disease activity. The change from Baseline is calculated, a negative value indicating improvement and a positive value worsening.

    Time frame: From Baseline to Visit 9 (up to Day 29)

07

Results

Posted Aug 3, 2021

Participant flow

The study started to enroll patients in May 2017 and concluded in August 2018.

Dosing Period 1
Participant flow — Dosing Period 1
MilestonePlaceboUCB7665 (7 mg/kg)Placebo - UCB7665 (7 mg/kg)Placebo - UCB7665 (4 mg/kg)UCB7665 (7 mg/kg) - UCB7665 (7 mg/kg)UCB7665 (7 mg/kg) - UCB7665 (4 mg/kg)
Started22210000
Completed period 122210000
Completed period 1 and started period 222200000
Completed22200000
Not completed010000
Withdrew: Adverse event010000
Dosing Period 2
Participant flow — Dosing Period 2
MilestonePlaceboUCB7665 (7 mg/kg)Placebo - UCB7665 (7 mg/kg)Placebo - UCB7665 (4 mg/kg)UCB7665 (7 mg/kg) - UCB7665 (7 mg/kg)UCB7665 (7 mg/kg) - UCB7665 (4 mg/kg)
Started0011111010
Completed008111010
Not completed003000
Withdrew: Adverse event003000
Observation Period
Participant flow — Observation Period
MilestonePlaceboUCB7665 (7 mg/kg)Placebo - UCB7665 (7 mg/kg)Placebo - UCB7665 (4 mg/kg)UCB7665 (7 mg/kg) - UCB7665 (7 mg/kg)UCB7665 (7 mg/kg) - UCB7665 (4 mg/kg)
Started222111111010
Completed22211111910
Not completed000010
Withdrew: Adverse event000010

Outcome measures

PrimaryChange From Baseline in Quantitative Myasthenia Gravis (QMG) Score to Visit 9

The total QMG score was obtained by summing the responses to each individual item (13 items; Responses: None=0, Mild=1, Moderate=2, Severe=3). The score ranges from 0 to 39, with lower scores indicating lower disease activity. The change from Baseline is calculated, a negative value indicating improvement and a positive value worsening.

Time frame:
From Baseline to Visit 9 (up to Day 29)
Reported as:
Least squares mean · scores on a scale
Change From Baseline in Quantitative Myasthenia Gravis (QMG) Score to Visit 9
scores on a scalePlacebo (FAS)UCB7665 (7 mg/kg) (FAS)
Change From Baseline in Quantitative Myasthenia Gravis (QMG) Score to Visit 9-1.2 ± 0.6-1.8 ± 0.6
Statistical analysis
  • Placebo (FAS) vs UCB7665 (7 mg/kg) (FAS) · MMRM · p = =0.221 (One-sided p-value was presented for difference.) · Ls mean difference vs placebo: -0.7Estimate included treatment and treatment by visit interaction effects.
SecondaryChange From Baseline in Myasthenia Gravis-Composite Score to Visit 9

The total Myasthenia Gravis (MG)-composite score was obtained by summing the responses to each individual item (10 items; Grade: 0-9 depending on item). The score ranges from 0 to 50, with lower scores indicating lower disease activity. The change from Baseline is calculated, a negative value indicating improvement and a positive value worsening.

Time frame:
From Baseline to Visit 9 (up to Day 29)
Reported as:
Least squares mean · scores on a scale
Change From Baseline in Myasthenia Gravis-Composite Score to Visit 9
scores on a scalePlacebo (FAS)UCB7665 (7 mg/kg) (FAS)
Change From Baseline in Myasthenia Gravis-Composite Score to Visit 9-1.2 ± 0.9-3.1 ± 0.9
Statistical analysis
  • Placebo (FAS) vs UCB7665 (7 mg/kg) (FAS) · MMRM · p = =0.089 (One-sided p-value was presented for difference.) · Ls mean difference vs placebo: -1.8Estimate included treatment and treatment by visit interaction effects.
SecondaryChange From Baseline in Myasthenia Gravis-Activities of Daily Living (MGADL) Score to Visit 9

The total MGDAL score was obtained by summing the responses to each individual item (8 items; Grades: 0, 1, 2, 3). The score ranges from 0 to 24, with lower scores indicating lower disease activity. The change from Baseline is calculated, a negative value indicating improvement and a positive value worsening.

Time frame:
From Baseline to Visit 9 (up to Day 29)
Reported as:
Least squares mean · scores on a scale
Change From Baseline in Myasthenia Gravis-Activities of Daily Living (MGADL) Score to Visit 9
scores on a scalePlacebo (FAS)UCB7665 (7 mg/kg) (FAS)
Change From Baseline in Myasthenia Gravis-Activities of Daily Living (MGADL) Score to Visit 9-0.4 ± 0.5-1.8 ± 0.5
Statistical analysis
  • Placebo (FAS) vs UCB7665 (7 mg/kg) (FAS) · ANCOVA · p = =0.036 (One-sided p-value was presented for difference.) · Ls mean difference vs placebo: -1.4Estimate included treatment effect.

Adverse events

Collected over From the start of Treatment Period at Baseline and up to Observation Period at 8 weeks after the final dose of IMP.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo (SS)0/22 (0%)2/22 (9.1%)7/22 (31.8%)
UCB7665 (7 mg/kg) (SS)0/21 (0%)0/21 (0%)13/21 (61.9%)
Placebo - UCB7665 (7 mg/kg) (SS)0/11 (0%)3/11 (27.3%)7/11 (63.6%)
Placebo - UCB7665 (4 mg/kg) (SS)0/11 (0%)1/11 (9.1%)9/11 (81.8%)
UCB7665 (7 mg/kg) - UCB7665 (7 mg/kg) (SS)0/10 (0%)1/10 (10%)8/10 (80%)
UCB7665 (7 mg/kg) - UCB7665 (4 mg/kg) (SS)0/10 (0%)0/10 (0%)9/10 (90%)
Most frequent serious events
Most frequent serious events
EventPlacebo (SS)UCB7665 (7 mg/kg) (SS)Placebo - UCB7665 (7 mg/kg) (SS)Placebo - UCB7665 (4 mg/kg) (SS)UCB7665 (7 mg/kg) - UCB7665 (7 mg/kg) (SS)UCB7665 (7 mg/kg) - UCB7665 (4 mg/kg) (SS)
Myasthenia gravis crisisNervous system disorders0/220/210/110/111/100/10
Ulna fractureInjury, poisoning and procedural complications0/220/211/110/110/100/10
HeadacheNervous system disorders0/220/211/110/110/100/10
Myasthenia gravisNervous system disorders1/220/211/111/110/100/10
PresyncopeNervous system disorders1/220/210/110/110/100/10
Most frequent other events
Showing 10 of 58
Most frequent other events
EventPlacebo (SS)UCB7665 (7 mg/kg) (SS)Placebo - UCB7665 (7 mg/kg) (SS)Placebo - UCB7665 (4 mg/kg) (SS)UCB7665 (7 mg/kg) - UCB7665 (7 mg/kg) (SS)UCB7665 (7 mg/kg) - UCB7665 (4 mg/kg) (SS)
HeadacheNervous system disorders3/2212/213/112/114/104/10
DiarrhoeaGastrointestinal disorders2/223/211/114/111/102/10
NauseaGastrointestinal disorders0/222/210/110/111/102/10
VomitingGastrointestinal disorders0/220/210/110/112/100/10
DizzinessNervous system disorders3/220/210/110/112/101/10
Myasthenic syndromeNervous system disorders0/220/210/110/112/101/10
Muscular weaknessMusculoskeletal and connective tissue disorders0/220/212/110/110/101/10
DyspnoeaRespiratory, thoracic and mediastinal disorders0/220/210/112/111/100/10
FatigueGeneral disorders3/220/211/111/110/100/10
NasopharyngitisInfections and infestations3/220/210/110/111/100/10

Baseline characteristics

Baseline Characteristics refer to the Randomized Set (RS) which consisted of all participants randomized into the study at the first randomization visit.

Age, Categorical
Age, Categorical(Participants)PlaceboUCB7665 (7 mg/kg)Total Title
<=18 years000
Between 18 and 65 years141832
>=65 years8311
Age, Continuous
Age, Continuous(years)PlaceboUCB7665 (7 mg/kg)Total Title
Mean53.3 ± 15.750.5 ± 14.751.9 ± 15.1
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboUCB7665 (7 mg/kg)Total Title
Female141327
Male8816
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboUCB7665 (7 mg/kg)Total Title
Asian101
Black112
White192039
Other/mixed101
08

Study locations

20 sites
  • Mg0002 712
    Los Angeles, California 90033, United States
  • Mg0002 701
    Orange, California 92868, United States
  • Mg0002 713
    Miami, Florida 33136, United States
  • Mg0002 708
    Tampa, Florida 33612, United States
  • Mg0002 707
    Augusta, Georgia 30912, United States
  • Mg0002 704
    Columbus, Ohio 43210, United States
  • Mg0002 102
    Bruxelles, Belgium
  • Mg0002 103
    Gent, Belgium
  • Mg0002 101
    Leuven, Belgium
  • Mg0002 203
    London, Canada
  • Mg0002 202
    Montréal, Canada
  • Mg0002 201
    Toronto, Canada
  • Mg0002 302
    Ostrava-Poruba, Czechia
  • Mg0002 401
    Aarhus, Denmark
  • Mg0002 402
    Copenhagen, Denmark
  • Mg0002 505
    Düsseldorf, Germany
  • Mg0002 502
    Gummersbach, Germany
  • Mg0002 501
    Jena, Germany
  • Mg0002 601
    Barcelona, Spain
  • Mg0002 602
    Barcelona, Spain
09

References and documents

Publications

  • Bril V, Benatar M, Andersen H, Vissing J, Brock M, Greve B, Kiessling P, Woltering F, Griffin L, Van den Bergh P; MG0002 Investigators. Efficacy and Safety of Rozanolixizumab in Moderate to Severe Generalized Myasthenia Gravis: A Phase 2 Randomized Control Trial. Neurology. 2021 Feb 9;96(6):e853-e865. doi: 10.1212/WNL.0000000000011108. Epub 2020 Nov 20. PubMed 33219142 ↗
  • Smith B, Kiessling A, Lledo-Garcia R, Dixon KL, Christodoulou L, Catley MC, Atherfold P, D'Hooghe LE, Finney H, Greenslade K, Hailu H, Kevorkian L, Lightwood D, Meier C, Munro R, Qureshi O, Sarkar K, Shaw SP, Tewari R, Turner A, Tyson K, West S, Shaw S, Brennan FR. Generation and characterization of a high affinity anti-human FcRn antibody, rozanolixizumab, and the effects of different molecular formats on the reduction of plasma IgG concentration. MAbs. 2018 Oct;10(7):1111-1130. doi: 10.1080/19420862.2018.1505464. Epub 2018 Sep 12. PubMed 30130439 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2017 to primary completion in May 2018, 12 months.

Results were first posted in Aug 2021, 3 years 2 months after primary completion. A results delay was requested in May 2019.

Of 22 phase 2 interventional studies under Myasthenia Gravis, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 30. This study's 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 10, 2017
First posted
Feb 14, 2017
StartActual
May 15, 2017
Primary completionActual
May 31, 2018
CompletionActual
Aug 6, 2018
Results delay requested
May 29, 2019
Results first posted
Aug 3, 2021
Last update
Aug 3, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 3, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03052751
Responsible party
Sponsor
First posted
Feb 14, 2017
Start date
May 15, 2017
Primary completion
May 31, 2018
Completion
Aug 6, 2018
Results posted
Aug 3, 2021
Last update
Aug 3, 2021

Study contacts

UCB Cares
study director · +1 877 822 9493 (UCB)

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rozanolixizumab

Start the discussion